Background: Bullous pemphigoid (BP) is a rare autoimmune blistering disease predominantly affecting the elderly population.
Objectives: The present study aims to identify clinical factors that may influence outcomes of BP, including skin phenotype, serology, mucosal involvement, pruritus, and triggers.
Methods: A retrospective analysis was conducted on 70 cases with BP registered from January 2019 to December 2022.
Objectives: Most patients in palliative oncology care are polymorbid and thus treated with multiple drugs. The therapeutic effect and safety of these drugs can be compromised by drug/drug interactions, but also by wider problems such as polypharmacy and compliance. The clinical pharmacist is, therefore, responsible for risk analysis and prevention.
View Article and Find Full Text PDFBratisl Lek Listy
October 2021
Objectives: The aim of the study was to analyse the diagnostic performance of the basophil activation test (BAT), to compare the diagnostic reliability of BATs performed with different types of allergens, which are available in Slovakia and to verify the correlation between the symptom severity and the sensitivity and specificity of the BAT in 114 patients with suspected hymenoptera venom allergy (HVA).
Background: Diagnosis of the HVA and the identification of the appropriate venom for immunotherapy are in Slovakia based on detailed patient'medical history, skin tests and detection of sIgE. In unclear cases, where the clinical decision regarding the relevant insect species for immunotherapy is difficult, the cellular tests are recommended in several countries, such as Sweden, Spain, Germany, Denmark and Italy.
Fibre reinforced polymer (FRP) rods are widely used as corrosion-resistant reinforcing in civil structures. However, developing a method to determine the loads on in-service FRP rods remains a challenge. In this study, the entropy of acoustic emission (AE) emanating from FRP rods is used to estimate the applied loads.
View Article and Find Full Text PDFBackground: Interleukin 17 is involved in the pathogenesis of psoriasis, a chronic debilitating disease.
Objectives: To evaluate the safety/tolerability, immunogenicity, pharmacokinetics/pharmacodynamics, and efficacy of M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe plaque psoriasis.
Methods: This multicenter, double-blind, placebo-controlled dose escalation phase 1 study randomized 44 patients 4:1 to treatment with subcutaneous M1095 (30, 60, 120, or 240 mg) or placebo biweekly for 6 weeks, in 4 ascending dose cohorts.